



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
A61K 45/06 ^(2006.01) **G01N 33/00** ^(2006.01)
A61K 31/7064 ^(2006.01) **A61K 31/7088** ^(2006.01)
A61K 31/713 ^(2006.01) **A61P 35/00** ^(2006.01)
A61P 35/02 ^(2006.01) **A61K 31/00** ^(2006.01)
A61K 38/00 ^(2006.01) **A61K 38/19** ^(2006.01)

(48) Corrigendum issued on:
04.03.2020 Bulletin 2020/10

(45) Date of publication and mention
of the grant of the patent:
01.01.2020 Bulletin 2020/01

(21) Application number: **17167295.9**

(22) Date of filing: **20.04.2017**

(54) **INTRACELLULAR KINASE SIK3 ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR
IMMUNE RESPONSES, AND USES THEREOF**

MIT RESISTENZ GEGEN KREBSIMMUNANTWORTEN ASSOZIIERTE INTRAZELLULÄRE KINASE
SIK3 UND VERWENDUNGEN DAVON

KINASE INTRACELLULAIRE SIK3 ASSOCIÉE À UNE RÉSISTANCE CONTRE DES RÉPONSES
IMMUNITAIRES ANTI-TUMEUR ET LEURS UTILISATIONS

(84) Designated Contracting States:
BE CH DE DK FR GB IE LI LU NL SE

(43) Date of publication of application:
24.10.2018 Bulletin 2018/43

(73) Proprietor: **iOmx Therapeutics AG**
82152 Martinsried (DE)

(72) Inventors:
• **Sorrentino, Antonio**
93051 Regensburg (DE)
• **Beckhove, Philipp**
93059 Regensburg (DE)
• **Michels, Tillmann**
93049 Regensburg (DE)
• **Khandelwal, Nisit**
85152 Martinsried (DE)
• **Boutros, Michael**
67117 Heidelberg (DE)
• **Breinig, Marco**
69198 Schriesheim (DE)
• **Sennhenn, Peter**
85152 Martinsried (DE)

• **Meier-Ewert, Sebastian**
82152 Martinsried (DE)
• **Volpin, Valentina**
93053 Regensburg (DE)
• **Menevse, Ayse**
93049 Regensburg (DE)

(74) Representative: **Kuttenkeuler, David**
Boehmert & Boehmert
Anwaltpartnerschaft mbB
Pettenkoferstrasse 22
80336 München (DE)

(56) References cited:
WO-A1-2017/043633 US-A1- 2016 081 989

• **JORGE E. CORTES ET AL: "Long-term bosutinib
for chronic phase chronic myeloid leukemia after
failure of imatinib plus dasatinib and/or nilotinib :
Third-/fourth-line bosutinib for chronic phase
CML", AMERICAN JOURNAL OF HEMATOLOGY,
vol. 91, no. 12, 1 December 2016 (2016-12-01),
pages 1206-1214, XP055417212, US ISSN:
0361-8609, DOI: 10.1002/ajh.24536**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- S CHAROENFUPRASERT ET AL: "Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer", ONCOGENE, vol. 30, no. 33, 14 March 2011 (2011-03-14), pages 3570-3584, XP055444336, ISSN: 0950-9232, DOI: 10.1038/onc.2011.77
- T. B. SUNDBERG ET AL: "Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 111, no. 34, 11 August 2014 (2014-08-11), pages 12468-12473, XP055444431, US ISSN: 0027-8424, DOI: 10.1073/pnas.1412308111